We have located links that may give you full text access.
English Abstract
Journal Article
[Potential to predict the risk of developing proliferative vitreoretinopathy with the analysis of clinical factors of regmatogenous retinal detachments].
Archivos de la Sociedad Española de Oftalmología 2000 December
PURPOSE: To investigate the possibility of classifying RD patients in different risk groups according to their probability of developing PVR.
METHODS: This retrospective study included 298 RD patients who underwent RD surgery, with either no PVR or with PVR grade B or less. Risk factors were evaluated by single and multiple logistic regression analysis to obtain risk factors of PVR. According to the results of the regression analysis, a score was applied to the different risk factors. The sum of these scores provided a final score for each patient, which was used to divide patients in three groups according to their risk of developing PVR.
RESULTS: By multiple logistic regression analysis, the following risk factors for developing PVR were identified: Preoperative PVR grade A or B, RD involving 4 quadrants, previous intraocular surgery, endolaser application, and intraocular gas injection. Three protective factors were also identified: RD in the fellow eye, postoperative ocular hypertension, and total reattachment 24 hours after surgery. Patients were divided in three groups according to their probability to develop PVR: Low risk (192 patients, 11.5% developed PVR), moderate risk (70 patients, 50.0% developed PVR) and high risk (36 patients, 80.6% developed PVR).
CONCLUSIONS: It is possible to ascribe patients to a low, moderate or high risk probability of developing PVR and these data could be useful to establish a prophylactic treatment for PVR. A larger and prospective study is needed to corroborate these data and to obtain new indicators.
METHODS: This retrospective study included 298 RD patients who underwent RD surgery, with either no PVR or with PVR grade B or less. Risk factors were evaluated by single and multiple logistic regression analysis to obtain risk factors of PVR. According to the results of the regression analysis, a score was applied to the different risk factors. The sum of these scores provided a final score for each patient, which was used to divide patients in three groups according to their risk of developing PVR.
RESULTS: By multiple logistic regression analysis, the following risk factors for developing PVR were identified: Preoperative PVR grade A or B, RD involving 4 quadrants, previous intraocular surgery, endolaser application, and intraocular gas injection. Three protective factors were also identified: RD in the fellow eye, postoperative ocular hypertension, and total reattachment 24 hours after surgery. Patients were divided in three groups according to their probability to develop PVR: Low risk (192 patients, 11.5% developed PVR), moderate risk (70 patients, 50.0% developed PVR) and high risk (36 patients, 80.6% developed PVR).
CONCLUSIONS: It is possible to ascribe patients to a low, moderate or high risk probability of developing PVR and these data could be useful to establish a prophylactic treatment for PVR. A larger and prospective study is needed to corroborate these data and to obtain new indicators.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app